<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en" xml:lang="en"><head>

<meta charset="utf-8">
<meta name="generator" content="quarto-1.2.335">

<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes">


<title>Type 2 diabetes in migrants: register-based analyses - 1&nbsp; Introduction</title>
<style>
code{white-space: pre-wrap;}
span.smallcaps{font-variant: small-caps;}
div.columns{display: flex; gap: min(4vw, 1.5em);}
div.column{flex: auto; overflow-x: auto;}
div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
ul.task-list{list-style: none;}
ul.task-list li input[type="checkbox"] {
  width: 0.8em;
  margin: 0 0.8em 0.2em -1.6em;
  vertical-align: middle;
}
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>


<script src="site_libs/quarto-nav/quarto-nav.js"></script>
<script src="site_libs/quarto-nav/headroom.min.js"></script>
<script src="site_libs/clipboard/clipboard.min.js"></script>
<script src="site_libs/quarto-search/autocomplete.umd.js"></script>
<script src="site_libs/quarto-search/fuse.min.js"></script>
<script src="site_libs/quarto-search/quarto-search.js"></script>
<meta name="quarto:offset" content="./">
<link href="./2-aims.html" rel="next">
<link href="./0-abbreviations.html" rel="prev">
<script src="site_libs/quarto-html/quarto.js"></script>
<script src="site_libs/quarto-html/popper.min.js"></script>
<script src="site_libs/quarto-html/tippy.umd.min.js"></script>
<script src="site_libs/quarto-html/anchor.min.js"></script>
<link href="site_libs/quarto-html/tippy.css" rel="stylesheet">
<link href="site_libs/quarto-html/quarto-syntax-highlighting.css" rel="stylesheet" id="quarto-text-highlighting-styles">
<script src="site_libs/bootstrap/bootstrap.min.js"></script>
<link href="site_libs/bootstrap/bootstrap-icons.css" rel="stylesheet">
<link href="site_libs/bootstrap/bootstrap.min.css" rel="stylesheet" id="quarto-bootstrap" data-mode="light">
<script id="quarto-search-options" type="application/json">{
  "location": "sidebar",
  "copy-button": false,
  "collapse-after": 3,
  "panel-placement": "start",
  "type": "textbox",
  "limit": 20,
  "language": {
    "search-no-results-text": "No results",
    "search-matching-documents-text": "matching documents",
    "search-copy-link-title": "Copy link to search",
    "search-hide-matches-text": "Hide additional matches",
    "search-more-match-text": "more match in this document",
    "search-more-matches-text": "more matches in this document",
    "search-clear-button-title": "Clear",
    "search-detached-cancel-button-title": "Cancel",
    "search-submit-button-title": "Submit"
  }
}</script>

  <script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-chtml-full.js" type="text/javascript"></script>

</head>

<body class="nav-sidebar floating">

<div id="quarto-search-results"></div>
  <header id="quarto-header" class="headroom fixed-top">
  <nav class="quarto-secondary-nav" data-bs-toggle="collapse" data-bs-target="#quarto-sidebar" aria-controls="quarto-sidebar" aria-expanded="false" aria-label="Toggle sidebar navigation" onclick="if (window.quartoToggleHeadroom) { window.quartoToggleHeadroom(); }">
    <div class="container-fluid d-flex justify-content-between">
      <h1 class="quarto-secondary-nav-title"><span class="chapter-number">1</span>&nbsp; <span class="chapter-title">Introduction</span></h1>
      <button type="button" class="quarto-btn-toggle btn" aria-label="Show secondary navigation">
        <i class="bi bi-chevron-right"></i>
      </button>
    </div>
  </nav>
</header>
<!-- content -->
<div id="quarto-content" class="quarto-container page-columns page-rows-contents page-layout-article">
<!-- sidebar -->
  <nav id="quarto-sidebar" class="sidebar collapse sidebar-navigation floating overflow-auto">
    <div class="pt-lg-2 mt-2 text-left sidebar-header">
    <div class="sidebar-title mb-0 py-0">
      <a href="./">Type 2 diabetes in migrants: register-based analyses</a> 
    </div>
      </div>
      <div class="mt-2 flex-shrink-0 align-items-center">
        <div class="sidebar-search">
        <div id="quarto-search" class="" title="Search"></div>
        </div>
      </div>
    <div class="sidebar-menu-container"> 
    <ul class="list-unstyled mt-1">
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./index.html" class="sidebar-item-text sidebar-link">Cover Page</a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./0-disclosure.html" class="sidebar-item-text sidebar-link">Financial disclosure</a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./0-preface.html" class="sidebar-item-text sidebar-link">Preface</a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./0-abbreviations.html" class="sidebar-item-text sidebar-link">Abbreviations</a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./1-introduction.html" class="sidebar-item-text sidebar-link active"><span class="chapter-number">1</span>&nbsp; <span class="chapter-title">Introduction</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./2-aims.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">2</span>&nbsp; <span class="chapter-title">Aims</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./3-methods.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">3</span>&nbsp; <span class="chapter-title">Material and methods</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./4-results.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">4</span>&nbsp; <span class="chapter-title">Results in summary</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./5-discussion-methods.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">5</span>&nbsp; <span class="chapter-title">Discussion of methods</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./6-discussion-results.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">6</span>&nbsp; <span class="chapter-title">Discussion of results</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./7-conclusions.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">7</span>&nbsp; <span class="chapter-title">Conclusions and implications</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./8-perspectives.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">8</span>&nbsp; <span class="chapter-title">Perspectives and future research</span></a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./references.html" class="sidebar-item-text sidebar-link">References</a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./summary-english.html" class="sidebar-item-text sidebar-link">English summary</a>
  </div>
</li>
        <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./summary-danish.html" class="sidebar-item-text sidebar-link">Dansk resumé</a>
  </div>
</li>
        <li class="sidebar-item sidebar-item-section">
      <div class="sidebar-item-container"> 
            <a class="sidebar-item-text sidebar-link text-start" data-bs-toggle="collapse" data-bs-target="#quarto-sidebar-section-1" aria-expanded="true">Appendices</a>
          <a class="sidebar-item-toggle text-start" data-bs-toggle="collapse" data-bs-target="#quarto-sidebar-section-1" aria-expanded="true">
            <i class="bi bi-chevron-right ms-2"></i>
          </a> 
      </div>
      <ul id="quarto-sidebar-section-1" class="collapse list-unstyled sidebar-section depth1 show">  
          <li class="sidebar-item">
  <div class="sidebar-item-container"> 
  <a href="./app1-supplementary.html" class="sidebar-item-text sidebar-link"><span class="chapter-number">A</span>&nbsp; <span class="chapter-title">Supplementary material</span></a>
  </div>
</li>
      </ul>
  </li>
    </ul>
    </div>
</nav>
<!-- margin-sidebar -->
    <div id="quarto-margin-sidebar" class="sidebar margin-sidebar">
        <nav id="TOC" role="doc-toc" class="toc-active">
    <h2 id="toc-title">Table of contents</h2>
   
  <ul>
  <li><a href="#migrants-and-type-2-diabetes" id="toc-migrants-and-type-2-diabetes" class="nav-link active" data-scroll-target="#migrants-and-type-2-diabetes"><span class="toc-section-number">1.1</span>  Migrants and type 2 diabetes</a></li>
  <li><a href="#type-2-diabetes-care" id="toc-type-2-diabetes-care" class="nav-link" data-scroll-target="#type-2-diabetes-care"><span class="toc-section-number">1.2</span>  Type 2 diabetes care</a>
  <ul class="collapse">
  <li><a href="#complications-and-risk-factors" id="toc-complications-and-risk-factors" class="nav-link" data-scroll-target="#complications-and-risk-factors"><span class="toc-section-number">1.2.1</span>  Complications and risk factors</a></li>
  <li><a href="#pharmacological-treatment" id="toc-pharmacological-treatment" class="nav-link" data-scroll-target="#pharmacological-treatment"><span class="toc-section-number">1.2.2</span>  Pharmacological treatment</a></li>
  <li><a href="#monitoring" id="toc-monitoring" class="nav-link" data-scroll-target="#monitoring"><span class="toc-section-number">1.2.3</span>  Monitoring</a></li>
  </ul></li>
  <li><a href="#clinical-guidelines-for-type-2-diabetes-care" id="toc-clinical-guidelines-for-type-2-diabetes-care" class="nav-link" data-scroll-target="#clinical-guidelines-for-type-2-diabetes-care"><span class="toc-section-number">1.3</span>  Clinical guidelines for type 2 diabetes care</a>
  <ul class="collapse">
  <li><a href="#diagnosis" id="toc-diagnosis" class="nav-link" data-scroll-target="#diagnosis"><span class="toc-section-number">1.3.1</span>  Diagnosis</a></li>
  <li><a href="#monitoring-1" id="toc-monitoring-1" class="nav-link" data-scroll-target="#monitoring-1"><span class="toc-section-number">1.3.2</span>  Monitoring</a></li>
  <li><a href="#biomarker-levels" id="toc-biomarker-levels" class="nav-link" data-scroll-target="#biomarker-levels"><span class="toc-section-number">1.3.3</span>  Biomarker levels</a></li>
  <li><a href="#pharmacological-treatment-1" id="toc-pharmacological-treatment-1" class="nav-link" data-scroll-target="#pharmacological-treatment-1"><span class="toc-section-number">1.3.4</span>  Pharmacological treatment</a></li>
  </ul></li>
  <li><a href="#identification-of-type-2-diabetes-cases-in-healthcare-registers" id="toc-identification-of-type-2-diabetes-cases-in-healthcare-registers" class="nav-link" data-scroll-target="#identification-of-type-2-diabetes-cases-in-healthcare-registers"><span class="toc-section-number">1.4</span>  Identification of type 2 diabetes cases in healthcare registers</a>
  <ul class="collapse">
  <li><a href="#benefits" id="toc-benefits" class="nav-link" data-scroll-target="#benefits"><span class="toc-section-number">1.4.1</span>  Benefits</a></li>
  <li><a href="#challenges" id="toc-challenges" class="nav-link" data-scroll-target="#challenges"><span class="toc-section-number">1.4.2</span>  Challenges</a></li>
  <li><a href="#register-based-diabetes-classifiers" id="toc-register-based-diabetes-classifiers" class="nav-link" data-scroll-target="#register-based-diabetes-classifiers"><span class="toc-section-number">1.4.3</span>  Register-based diabetes classifiers</a></li>
  </ul></li>
  <li><a href="#introduction-at-a-glance" id="toc-introduction-at-a-glance" class="nav-link" data-scroll-target="#introduction-at-a-glance"><span class="toc-section-number">1.5</span>  Introduction at a glance</a></li>
  </ul>
</nav>
    </div>
<!-- main -->
<main class="content" id="quarto-document-content">

<header id="title-block-header" class="quarto-title-block default">
<div class="quarto-title">
<h1 class="title d-none d-lg-block"><span class="chapter-number">1</span>&nbsp; <span class="chapter-title">Introduction</span></h1>
</div>



<div class="quarto-title-meta">

    
  
    
  </div>
  

</header>

<p><em>[This paragraph should introduce the overall context, and very briefly introduce the aims/niche of the project: Why did I do this?]</em></p>
<p>This chapter describes type 2 diabetes (T2D) and how migrants are at particular risk. It also describes the context of care in Denmark and summarizes clinical guideline recommendations and how they relate to the needs of migrants with T2D. Finally, it introduces the reader to identification of diabetes patients in Danish healthcare registers as a means to provide much-needed knowledge on potential disparities in T2D care between migrants and native Danes.</p>
<section id="migrants-and-type-2-diabetes" class="level2" data-number="1.1">
<h2 data-number="1.1" class="anchored" data-anchor-id="migrants-and-type-2-diabetes"><span class="header-section-number">1.1</span> Migrants and type 2 diabetes</h2>
<p>T2D constitutes the vast majority of all diabetes cases, and disproportionally affects the socially deprived demographics in societies across the globe[manglerref]. The prevalence of type 2 diabetes (T2D) today exceeds half a <em>billion</em> people globally and is on the rise due to several factors, including population aging, urbanization, adoption of energy-dense diets, and sedentary lifestyles. These transitions are occurring at a rapid pace in developing countries, where they affect the largest number of people<span class="citation" data-cites="diabetesatlas"><sup><a href="references.html#ref-diabetesatlas" role="doc-biblioref">1</a></sup></span>. Many developing countries have populations with a genetic predisposition to developing T2D, which exacerbates the impact of these transitions.</p>
<p>Migrants are particularly vulnerable to T2D, as they are positioned at the point of convergence of these exposures: genetic predisposition, rapid lifestyle transitions, and the disparate social impact of T2D. After being granted residence permit in Denmark and other developed nations, migrants are often housed in densely-populated urban areas and exposed to drastic lifestyle transitions. Migrants may also suffer from previous mental and physical trauma, which - in addition to cultural and language barriers - can limit their ability to gain higher-income employment and escape their disadvantageous socioeconomic position.</p>
<p>In Denmark and many other developed nations, healthcare systems are facing a challenge to sustain the expected high quality of care in an aging population with a growing burden of chronic diseases and comorbidities. Prioritization of limited resources is crucial to ensure that those with the highest need for (and potential benefit from) healthcare receive adequate care. Migrant origin is a well-established risk factor of T2D, and migrants have a higher prevalence of T2D compared to native populations today[manglerref], but the increased risk of developing T2D is partially mitigated by their younger age. However, this only delays the impact of their increased T2D risk, and as these migrant populations age in the coming years, they will make up a growing proportion of T2D patients in the country. Therefore, understanding potential disparities in care and the specific healthcare needs of migrant populations with T2D can inform the prioritization of healthcare resources, ultimately ensuring that all individuals with T2D can continue to receive appropriate care.</p>
<p>Currently, there is a lack of evidence on T2D care in migrants, and research in this area faces several challenges that may explain the scarsity of evidence. Not only are migrants a minority, which limits the size of potential study populations, they are often a hard-to-reach group in studies that require patient engagement for inclusion, which exacerbates sample size problems and can induce selection bias in such study designs. Furthermore, migrants have historically been defined by their racial appearance and ethnic minorities categorized accordingly, particularly in Europe and the United States. While these categories allow researchers to identify racial minorities, they obscure the role of migrants in the modern era, and provide only indirect evidence on migrant minority groups<span class="citation" data-cites="erayil2021raceethnicity"><sup><a href="references.html#ref-erayil2021raceethnicity" role="doc-biblioref">2</a></sup></span>.</p>
</section>
<section id="type-2-diabetes-care" class="level2" data-number="1.2">
<h2 data-number="1.2" class="anchored" data-anchor-id="type-2-diabetes-care"><span class="header-section-number">1.2</span> Type 2 diabetes care</h2>
<section id="complications-and-risk-factors" class="level3" data-number="1.2.1">
<h3 data-number="1.2.1" class="anchored" data-anchor-id="complications-and-risk-factors"><span class="header-section-number">1.2.1</span> Complications and risk factors</h3>
<section id="overall" class="level4" data-number="1.2.1.1">
<h4 data-number="1.2.1.1" class="anchored" data-anchor-id="overall"><span class="header-section-number">1.2.1.1</span> Overall</h4>
<p>Complications of diabetes are traditionally divided into macrovascular (e.g.&nbsp;<em>cardiovascular disease</em> (CVD)) and microvascular complications (e.g.&nbsp;kidney disease, retinopathy, neuropathy), all of which contribute to morbidity and mortality in T2D. Several lifestyle and physiological factors influence the risk of developing complications, and clinical care revolves around management of these. In addition to being key risk factors of complications, blood pressure and levels of <em>hemoglobin-A1C</em> (HbA1c) and <em>low-density lipoprotein cholesterol</em> (LDL-C) drive indications for treatment and clinical decision-making in T2D[manglerref].</p>
</section>
<section id="in-migrants" class="level4" data-number="1.2.1.2">
<h4 data-number="1.2.1.2" class="anchored" data-anchor-id="in-migrants"><span class="header-section-number">1.2.1.2</span> In migrants</h4>
<p>In European countries, HbA1c-levels are higher in migrants than in native populations[manglerref], but LDL-C levels have only been sparsely described. The evidence on complication risk is inconsistent, but indicates a higher risk compared to native populations, although risks differ between complication types, migrant groups and countries. Similarly, higher mortality among migrants with T2D has been reported in some studies <em>[refs]</em>, while other studies have found similar or lower risk [mangler<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563673/">refs</a>]</p>
</section>
</section>
<section id="pharmacological-treatment" class="level3" data-number="1.2.2">
<h3 data-number="1.2.2" class="anchored" data-anchor-id="pharmacological-treatment"><span class="header-section-number">1.2.2</span> Pharmacological treatment</h3>
<section id="overall-1" class="level4" data-number="1.2.2.1">
<h4 data-number="1.2.2.1" class="anchored" data-anchor-id="overall-1"><span class="header-section-number">1.2.2.1</span> Overall</h4>
<p>Due to their effects on HbA1c, LDL-C, and blood pressure, <em>glucose-lowering drugs</em> (GLD), <em>lipid-lowering drugs</em> (LLD), and antihypertensive drugs are critical parts of T2D care. In T2D patients with particularly high risk of complications, pharmacological treatment also includes <em>antiplatelet therapy</em> (APT), as the complication risk-lowering effect outweighs the risk of adverse events in these patients<span class="citation" data-cites="haller2011arb zoungas2011advance"><sup><a href="references.html#ref-haller2011arb" role="doc-biblioref">3</a>,<a href="references.html#ref-zoungas2011advance" role="doc-biblioref">4</a></sup></span>. In addition to their effect on biomarker levels, certain drug types within the above classes of drugs have other positive effects. In particular, the GLD types <em>sodium glucose co-transporter type 2 inhibitors</em> (SGLT2i) and <em>glucagon-like peptide-1 receptor agonists</em> (GLP1RA) substantially reduce the risk of adverse cardiovascular and renal events beyond their effect on HbA1c. Similarly, the antihypertensive drugs types <em>angiotensin-converting enzyme-inhibitors</em> (ACEI) and <em>angiotensin receptor blockers</em> (ARB) reduce the risk and improve the prognosis of <em>diabetic kidney disease</em> (DKD) beyond their effect on blood pressure. [manglerref]</p>
<p>Combination therapy - the use of multiple drug types with differing mechanisms of action - is a way to increase treatment intensity and achieve treatment goals with fewer side-effects. Combination therapy is particularly important in T2D, as GLD monotherapy fails to achieve target levels of HbA1c in many patients, even at maximal dosage. [manglerref]</p>
</section>
<section id="in-migrants-1" class="level4" data-number="1.2.2.2">
<h4 data-number="1.2.2.2" class="anchored" data-anchor-id="in-migrants-1"><span class="header-section-number">1.2.2.2</span> In migrants</h4>
<p>Evidence from several European countries shows that GLDs are prescribed earlier and/or to a larger proportion of migrants compared to native populations[manglerref]. However, disparities in the quality of the prescribed GLD treatment, such as the use of combination therapy or the types of GLD prescribed, has not been studied. Indirect evidence suggests that such disparities are likely, as non-white minorities in the UK were slower and less likely to intensify to combination therapy than white groups[manglerref9], and migrants in Italy with T2D purchased fewer packages of non-insulin GLD per person-year than their native counterparts[manglerref10], and socioeconomic[manglerref21-25] and racial[manglerref22, 24, 27] disparities in prescribing of SGLT2i and GLP1RA have been reported in several countries.</p>
<p>In contrast, studies from European countries have reported lower rates of prescribing of LLD in migrants with T2D <em>[care_qual_migrants refs 40, 5, Eastwood]</em>. Treatment with LLD is not indicated in all patients with T2D, however, and only a few of these studies accounted for treatment indication.</p>
<p>Evidence on ACEI/ARB use and APT in migrants with T2D is very limited, but a study from Italy found lower odds of treatment in most migrant groups [42], indicating a potential for disparities in these areas of care.</p>
</section>
</section>
<section id="monitoring" class="level3" data-number="1.2.3">
<h3 data-number="1.2.3" class="anchored" data-anchor-id="monitoring"><span class="header-section-number">1.2.3</span> Monitoring</h3>
<section id="overall-2" class="level4" data-number="1.2.3.1">
<h4 data-number="1.2.3.1" class="anchored" data-anchor-id="overall-2"><span class="header-section-number">1.2.3.1</span> Overall</h4>
<p>In T2D, timely monitoring of risk factors and complications allows faster adjustment of treatment, and monitoring has previously been used as a process indicator of care quality, although the direct evidence on its influence on outcomes is sparse. <em>[see refs</em> [<a href="https://dmsjournal.biomedcentral.com/articles/10.1186/s13098-019-0428-8">7-12</a>, e.g.&nbsp;https://doi.org/10.1093/intqhc/mzl023, , evt. DVDD rapport]*</p>
</section>
<section id="in-migrants-2" class="level4" data-number="1.2.3.2">
<h4 data-number="1.2.3.2" class="anchored" data-anchor-id="in-migrants-2"><span class="header-section-number">1.2.3.2</span> In migrants</h4>
<p>The evidence on monitoring of T2D in migrants is inconsistent between countries and different aspects of monitoring. In Norway, migrants with T2D received similar or more monitoring than native Norwegians[manglerrefTran2010], while migrants with T2D in Italy received fewer referrals for consultations than native Italians[manglerrefMarchesini2014].</p>
</section>
</section>
</section>
<section id="clinical-guidelines-for-type-2-diabetes-care" class="level2" data-number="1.3">
<h2 data-number="1.3" class="anchored" data-anchor-id="clinical-guidelines-for-type-2-diabetes-care"><span class="header-section-number">1.3</span> Clinical guidelines for type 2 diabetes care</h2>
<p>In Denmark, T2D care is most often provided by <em>general practitioners</em> (GPs) and other actors in the primary care sector, although some patients are treated in the outpatient hospital setting. The Danish College of General Practitioners publishes national clinical guidelines for T2D in cooperation with the Danish Endocrine Society. The guidelines are continuously updated as new evidence emerges. In this PhD project, T2D care was studied in the time period covered by the 2012<span class="citation" data-cites="dsam2012"><sup><a href="references.html#ref-dsam2012" role="doc-biblioref">5</a></sup></span> and 2019<span class="citation" data-cites="dsam2019"><sup><a href="references.html#ref-dsam2019" role="doc-biblioref">6</a></sup></span> revisions (only minor changes were made between the two revisions). These guidelines advise that monitoring intervals, biomarker goals and treatment intensity are adapted to fit the individual patient, but specify recommendations that may be used as indicators of care quality.</p>
<p>Danish guidelines provide virtually no specific recommendations on T2D care in migrants, and migrants are not addressed in the appendix on pharmacological treatment of special groups. Guideline recommendations relevant to this PhD study are described below.</p>
<section id="diagnosis" class="level3" data-number="1.3.1">
<h3 data-number="1.3.1" class="anchored" data-anchor-id="diagnosis"><span class="header-section-number">1.3.1</span> Diagnosis</h3>
<section id="overall-3" class="level4" data-number="1.3.1.1">
<h4 data-number="1.3.1.1" class="anchored" data-anchor-id="overall-3"><span class="header-section-number">1.3.1.1</span> Overall</h4>
<p>HbA1c values <span class="math inline">\(\ge48 mmol/mol\)</span> are diagnostic of diabetes, but diagnosis must be confirmed with a repeated sample on a different day. Once diagnosed, patients with T2D should be considered permanently affected by the disease, and the associated risk factors for complications should be treated regardless of subsequent normalization of HbA1c.</p>
</section>
<section id="in-migrants-3" class="level4" data-number="1.3.1.2">
<h4 data-number="1.3.1.2" class="anchored" data-anchor-id="in-migrants-3"><span class="header-section-number">1.3.1.2</span> In migrants</h4>
<p>Migrant origin is mentioned as a risk factor of T2D, and guidelines recommend increased HbA1c screening in certain migrant groups.</p>
</section>
</section>
<section id="monitoring-1" class="level3" data-number="1.3.2">
<h3 data-number="1.3.2" class="anchored" data-anchor-id="monitoring-1"><span class="header-section-number">1.3.2</span> Monitoring</h3>
<section id="overall-4" class="level4" data-number="1.3.2.1">
<h4 data-number="1.3.2.1" class="anchored" data-anchor-id="overall-4"><span class="header-section-number">1.3.2.1</span> Overall</h4>
<p>The risk biomarkers HbA1c and LDL-C should be measured yearly, as well as urine albumin-to-creatinine ratio (UACR) to screen for DKD. Repeated samples of UACR <span class="math inline">\(\ge 300mg/g\)</span> is considering diagnostic of diabetic kidney disease (DKD). Diabetic retinopathy should be screened by an ophthalmologist every second year and screening for diabetic foot disease by a podiatrist every year. At the initial diagnosis of T2D, a baseline-screening of all five types of monitoring is recommended.</p>
</section>
<section id="in-migrants-4" class="level4" data-number="1.3.2.2">
<h4 data-number="1.3.2.2" class="anchored" data-anchor-id="in-migrants-4"><span class="header-section-number">1.3.2.2</span> In migrants</h4>
<p>Guidelines provide no specific recommendations on monitoring in migrants.</p>
</section>
</section>
<section id="biomarker-levels" class="level3" data-number="1.3.3">
<h3 data-number="1.3.3" class="anchored" data-anchor-id="biomarker-levels"><span class="header-section-number">1.3.3</span> Biomarker levels</h3>
<section id="overall-5" class="level4" data-number="1.3.3.1">
<h4 data-number="1.3.3.1" class="anchored" data-anchor-id="overall-5"><span class="header-section-number">1.3.3.1</span> Overall</h4>
<p>For HbA1c, the goal should be the lowest possible level without hypoglycemia or inappropriate polypharmacy. Specific targets at <span class="math inline">\(48 mmol/mol\)</span>, <span class="math inline">\(53 mmol/mol\)</span>, <span class="math inline">\(58 mmol/mol\)</span>, and <span class="math inline">\(70 mmol/mol\)</span> are provided depending on diabetes duration and severity, complications, age and comorbidities.</p>
<p>For LDL-C, the level should be as low as possible. A general target below <span class="math inline">\(2.6mmol/L\)</span> is provided, while the target in patients with complications should be below <span class="math inline">\(1.8mmol/L\)</span>.</p>
</section>
<section id="in-migrants-5" class="level4" data-number="1.3.3.2">
<h4 data-number="1.3.3.2" class="anchored" data-anchor-id="in-migrants-5"><span class="header-section-number">1.3.3.2</span> In migrants</h4>
<p>Guidelines provide no specific recommendations on HbA1c or LDL-C targets in migrants.</p>
</section>
</section>
<section id="pharmacological-treatment-1" class="level3" data-number="1.3.4">
<h3 data-number="1.3.4" class="anchored" data-anchor-id="pharmacological-treatment-1"><span class="header-section-number">1.3.4</span> Pharmacological treatment</h3>
<section id="overall-6" class="level4" data-number="1.3.4.1">
<h4 data-number="1.3.4.1" class="anchored" data-anchor-id="overall-6"><span class="header-section-number">1.3.4.1</span> Overall</h4>
</section>
<section id="glucose-lowering-drugs" class="level4" data-number="1.3.4.2">
<h4 data-number="1.3.4.2" class="anchored" data-anchor-id="glucose-lowering-drugs"><span class="header-section-number">1.3.4.2</span> Glucose-lowering drugs</h4>
<p><strong>Combination therapy:</strong> GLD therapy is recommended in patients with HbA1c ≥ 48 mmol/mol, and metformin is the recommended first-line treatment. There is no overall recommendation of second- or third-line drugs, although SGLT2i or GLP1RA should be considered in patients with CVD when metformin or other treatment is insufficient to reach the patient’s HbA1c target (note that, although not in effect during the time period studied in this PhD project, the recommendations for SGLT2i and GLP1RA were expanded in the 2022 revision to include all T2D patients with CVD, multiple risk factors for CVD, or chronic kidney disease, irrespective of HbA1c level).</p>
<p><strong>Individual drug types:</strong> Guidelines recommend factoring in all effects - positive and negative - as well as cost when choosing between individual drug types, and do not present a fixed hierarchy between GLD drug type. [<em>maybe</em> <em>summarise guideline considerations on second- and third-line drugs, similar to</em> https://vejledninger.dsam.dk/media/238.png]</p>
</section>
<section id="lipid-lowering-drugs" class="level4" data-number="1.3.4.3">
<h4 data-number="1.3.4.3" class="anchored" data-anchor-id="lipid-lowering-drugs"><span class="header-section-number">1.3.4.3</span> Lipid-lowering drugs</h4>
<p>Treatment with LLD is recommended to all individuals with prevalent CVD, diabetic nephropathy, or LDL-C above 2.5 mmol/L.</p>
</section>
<section id="antihypertensive-drugs" class="level4" data-number="1.3.4.4">
<h4 data-number="1.3.4.4" class="anchored" data-anchor-id="antihypertensive-drugs"><span class="header-section-number">1.3.4.4</span> <strong>Antihypertensive drugs</strong></h4>
<p>In addition to treatment of hypertension, use of either ACEI or ARB is recommended in individuals with prevalent CVD, microalbuminuria, or diabetic kidney disease.</p>
</section>
<section id="antiplatelet-therapy" class="level4" data-number="1.3.4.5">
<h4 data-number="1.3.4.5" class="anchored" data-anchor-id="antiplatelet-therapy"><span class="header-section-number">1.3.4.5</span> Antiplatelet therapy</h4>
<p>APT is recommended in individuals with prevalent CVD, diabetic kidney disease or very high risk of CVD due to other risk factors (this recommendation was expanded in the 2022 revision to also include individuals with kidney failure and concurrent microalbuminuria).</p>
</section>
<section id="in-migrants-6" class="level4" data-number="1.3.4.6">
<h4 data-number="1.3.4.6" class="anchored" data-anchor-id="in-migrants-6"><span class="header-section-number">1.3.4.6</span> In migrants</h4>
<p>Guidelines provide no specific recommendations on any aspect of pharmacological treatment in migrants.</p>
</section>
</section>
</section>
<section id="identification-of-type-2-diabetes-cases-in-healthcare-registers" class="level2" data-number="1.4">
<h2 data-number="1.4" class="anchored" data-anchor-id="identification-of-type-2-diabetes-cases-in-healthcare-registers"><span class="header-section-number">1.4</span> Identification of type 2 diabetes cases in healthcare registers</h2>
<section id="benefits" class="level3" data-number="1.4.1">
<h3 data-number="1.4.1" class="anchored" data-anchor-id="benefits"><span class="header-section-number">1.4.1</span> Benefits</h3>
<p>Healthcare registers provide a powerful data source for population-wide studies without the need to engage the patient for inclusion. The ability to include all individuals in the population makes them particularly suited for studies of migrants with T2D, where sample size is a limiting factor and other data sources may be vulnerable to selection bias in these groups.</p>
</section>
<section id="challenges" class="level3" data-number="1.4.2">
<h3 data-number="1.4.2" class="anchored" data-anchor-id="challenges"><span class="header-section-number">1.4.2</span> Challenges</h3>
<p>General-purpose registers and other administrative databases often provide the basis of diabetes epidemiology, but rarely contain validated diabetes-specific data. If the diabetes-specific data is not accurate, bias may be induced into studies. Thus, it is important to have an accurate tool to identify individuals with diabetes in the registers, as findings may differ with various diabetes definitions. Considerable efforts have been made towards establishing such a tool for diabetes research in several countries, including Denmark.</p>
<p>Internationally, some algorithms classifying T1D and T2D have been validated in cohorts of individuals with diabetes, but none have been validated in a general population. In a general population, classification algorithms (classifiers) must not only discern type 1 diabetes (T1D) from T2D, but also identify diabetes while accounting for events that might lead to inclusion of non-cases, such as use of GLD in the treatment of other conditions. Currently, no type-specific diabetes classifier has been validated in a general population, which leaves register-based studies in this area vulnerable to biases.</p>
</section>
<section id="register-based-diabetes-classifiers" class="level3" data-number="1.4.3">
<h3 data-number="1.4.3" class="anchored" data-anchor-id="register-based-diabetes-classifiers"><span class="header-section-number">1.4.3</span> Register-based diabetes classifiers</h3>
<p>In Denmark, the first resource readily available to researchers to identify diabetes cases using register data was the National Diabetes Register, established in 2006. The National Diabetes Register was discontinued in 2012, and a later validation study questioned its validity and called for future registers to adopt inclusion based on elevated HbA1c levels.</p>
<p>Currently, the Register of Selected Chronic Diseases (RSCD) is the only publicly available resource to identify diabetes cases in Danish register data (by application to the Danish Health Data Authority), but it has not been publicly validated nor is the source code behind the algorithm publicly available. Notably, the algorithm lacks inclusion based on elevated HbA1c levels.</p>
</section>
</section>
<section id="introduction-at-a-glance" class="level2" data-number="1.5">
<h2 data-number="1.5" class="anchored" data-anchor-id="introduction-at-a-glance"><span class="header-section-number">1.5</span> Introduction at a glance</h2>
<p>T2D is a disease that carries serious risks, but several treatment options are available to control the risk factors in T2D and reduce the risk of complications and death. In an aging population, the burden of T2D on healthcare services is rising, and resources must be prioritized to those with higher needs to ensure adequate care.</p>
<p>Migrants are particularly vulnerable to T2D, having an increased prevalence of the disease compared to native Danes. Despite having higher HbA1c levels than their native counterparts, evidence on complication risk and mortality in migrants is inconsistent, but some evidence suggests a higher risk. Evidence on disparities in care that may contribute excess risk in migrants with T2D is limited, and research in this area faces several challenges that may explain this, such as limited sample sizes and migrants being hard-to-reach for intervention and survey studies. Register-based studies are well-suited to handle these limitations, but currently there is no validated method to identify T2D cases in a general population, which leaves register-based studies in this area vulnerable to biases.</p>
<p>In Denmark, guidelines are available to direct clinicians and patients towards the best possible outcomes while prioritizing resources. Despite the special challenges facing migrants, current guidelines do not contain specific recommendations for T2D care in migrants, perhaps due to the limited evidence on specific areas of T2D care where disparities between migrant groups and native Danes may be present.</p>


<div id="refs" class="references csl-bib-body" role="doc-bibliography" style="display: none">
<div id="ref-diabetesatlas" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">1. </div><div class="csl-right-inline">Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Research and Clinical Practice [Internet] 2022;183:109119. Available from: <a href="https://www.sciencedirect.com/science/article/pii/S0168822721004782">https://www.sciencedirect.com/science/article/pii/S0168822721004782</a></div>
</div>
<div id="ref-erayil2021raceethnicity" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">2. </div><div class="csl-right-inline">Erayil SE, Smith MK, Gebreslasse T, et al. The value and interpretation of race and ethnicity data in the era of global migration: A change is in order. The American Journal of Tropical Medicine and Hygiene [Internet] 2021;105(6):1453–5. Available from: <a href="https://www.ajtmh.org/view/journals/tpmd/105/6/article-p1453.xml">https://www.ajtmh.org/view/journals/tpmd/105/6/article-p1453.xml</a></div>
</div>
<div id="ref-haller2011arb" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">3. </div><div class="csl-right-inline">Haller H, Ito S, Izzo JL, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. New England Journal of Medicine [Internet] 2011;364(10):907–17. Available from: <a href="https://doi.org/10.1056/NEJMoa1007994">https://doi.org/10.1056/NEJMoa1007994</a></div>
</div>
<div id="ref-zoungas2011advance" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">4. </div><div class="csl-right-inline">Zoungas S, Galan BE de, Ninomiya T, et al. <span class="nocase">Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes: New results from the ADVANCE trial</span>. Diabetes Care [Internet] 2009;32(11):2068–74. Available from: <a href="https://doi.org/10.2337/dc09-0959">https://doi.org/10.2337/dc09-0959</a></div>
</div>
<div id="ref-dsam2012" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">5. </div><div class="csl-right-inline">The Danish College of General Practitioners [Dansk Selskab for Almen Medicin]. <span class="nocase">Type 2-diabetes - et metabolisk syndrom [Danish]</span> [Internet]. {2012; last accessed on 7 Feb 2023};Available from: <a href="https://vejledninger.dsam.dk/media/files/20/type-2-diabetes-2012-med-links.pdf">https://vejledninger.dsam.dk/media/files/20/type-2-diabetes-2012-med-links.pdf</a></div>
</div>
<div id="ref-dsam2019" class="csl-entry" role="doc-biblioentry">
<div class="csl-left-margin">6. </div><div class="csl-right-inline">The Danish College of General Practitioners [Dansk Selskab for Almen Medicin]. <span class="nocase">Type 2-diabetes - opfølgning og behandling [Danish]</span> [Internet]. {2019; last accessed on 7 Feb 2023};Available from: <a href="https://vejledninger.dsam.dk/type2/">https://vejledninger.dsam.dk/type2/</a></div>
</div>
</div>
</section>

</main> <!-- /main -->
<script id="quarto-html-after-body" type="application/javascript">
window.document.addEventListener("DOMContentLoaded", function (event) {
  const toggleBodyColorMode = (bsSheetEl) => {
    const mode = bsSheetEl.getAttribute("data-mode");
    const bodyEl = window.document.querySelector("body");
    if (mode === "dark") {
      bodyEl.classList.add("quarto-dark");
      bodyEl.classList.remove("quarto-light");
    } else {
      bodyEl.classList.add("quarto-light");
      bodyEl.classList.remove("quarto-dark");
    }
  }
  const toggleBodyColorPrimary = () => {
    const bsSheetEl = window.document.querySelector("link#quarto-bootstrap");
    if (bsSheetEl) {
      toggleBodyColorMode(bsSheetEl);
    }
  }
  toggleBodyColorPrimary();  
  const icon = "";
  const anchorJS = new window.AnchorJS();
  anchorJS.options = {
    placement: 'right',
    icon: icon
  };
  anchorJS.add('.anchored');
  const clipboard = new window.ClipboardJS('.code-copy-button', {
    target: function(trigger) {
      return trigger.previousElementSibling;
    }
  });
  clipboard.on('success', function(e) {
    // button target
    const button = e.trigger;
    // don't keep focus
    button.blur();
    // flash "checked"
    button.classList.add('code-copy-button-checked');
    var currentTitle = button.getAttribute("title");
    button.setAttribute("title", "Copied!");
    let tooltip;
    if (window.bootstrap) {
      button.setAttribute("data-bs-toggle", "tooltip");
      button.setAttribute("data-bs-placement", "left");
      button.setAttribute("data-bs-title", "Copied!");
      tooltip = new bootstrap.Tooltip(button, 
        { trigger: "manual", 
          customClass: "code-copy-button-tooltip",
          offset: [0, -8]});
      tooltip.show();    
    }
    setTimeout(function() {
      if (tooltip) {
        tooltip.hide();
        button.removeAttribute("data-bs-title");
        button.removeAttribute("data-bs-toggle");
        button.removeAttribute("data-bs-placement");
      }
      button.setAttribute("title", currentTitle);
      button.classList.remove('code-copy-button-checked');
    }, 1000);
    // clear code selection
    e.clearSelection();
  });
  function tippyHover(el, contentFn) {
    const config = {
      allowHTML: true,
      content: contentFn,
      maxWidth: 500,
      delay: 100,
      arrow: false,
      appendTo: function(el) {
          return el.parentElement;
      },
      interactive: true,
      interactiveBorder: 10,
      theme: 'quarto',
      placement: 'bottom-start'
    };
    window.tippy(el, config); 
  }
  const noterefs = window.document.querySelectorAll('a[role="doc-noteref"]');
  for (var i=0; i<noterefs.length; i++) {
    const ref = noterefs[i];
    tippyHover(ref, function() {
      // use id or data attribute instead here
      let href = ref.getAttribute('data-footnote-href') || ref.getAttribute('href');
      try { href = new URL(href).hash; } catch {}
      const id = href.replace(/^#\/?/, "");
      const note = window.document.getElementById(id);
      return note.innerHTML;
    });
  }
  const findCites = (el) => {
    const parentEl = el.parentElement;
    if (parentEl) {
      const cites = parentEl.dataset.cites;
      if (cites) {
        return {
          el,
          cites: cites.split(' ')
        };
      } else {
        return findCites(el.parentElement)
      }
    } else {
      return undefined;
    }
  };
  var bibliorefs = window.document.querySelectorAll('a[role="doc-biblioref"]');
  for (var i=0; i<bibliorefs.length; i++) {
    const ref = bibliorefs[i];
    const citeInfo = findCites(ref);
    if (citeInfo) {
      tippyHover(citeInfo.el, function() {
        var popup = window.document.createElement('div');
        citeInfo.cites.forEach(function(cite) {
          var citeDiv = window.document.createElement('div');
          citeDiv.classList.add('hanging-indent');
          citeDiv.classList.add('csl-entry');
          var biblioDiv = window.document.getElementById('ref-' + cite);
          if (biblioDiv) {
            citeDiv.innerHTML = biblioDiv.innerHTML;
          }
          popup.appendChild(citeDiv);
        });
        return popup.innerHTML;
      });
    }
  }
});
</script>
<nav class="page-navigation">
  <div class="nav-page nav-page-previous">
      <a href="./0-abbreviations.html" class="pagination-link">
        <i class="bi bi-arrow-left-short"></i> <span class="nav-page-text">Abbreviations</span>
      </a>          
  </div>
  <div class="nav-page nav-page-next">
      <a href="./2-aims.html" class="pagination-link">
        <span class="nav-page-text"><span class="chapter-number">2</span>&nbsp; <span class="chapter-title">Aims</span></span> <i class="bi bi-arrow-right-short"></i>
      </a>
  </div>
</nav>
</div> <!-- /content -->



</body></html>